Fasinumab

Summary

Fasinumab (CHEMBL2109528) is a phase-3 clinical-stage antibody; indicated across 7 conditions including osteoarthritis, knee and osteoarthritis, hip.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 7 conditions
• Clinical trials: 15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109528
Name	Fasinumab
Type	Antibody
Max phase	3

Also known as: Fasinumab, REGN-475, REGN475, SAR-164877, SAR164877, FASINUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoarthritis, knee	3	MONDO:0005416	EFO:0004616
osteoarthritis, hip	3	MONDO:0006629	EFO:1000786
sciatica	2	MONDO:0024333	HP:0011868
osteoarthritis	2	MONDO:0005178	MONDO:0005178

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE2	6
PHASE3	4
PHASE2/PHASE3	2
PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02447276	PHASE2/PHASE3	COMPLETED	Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip
NCT02620020	PHASE2/PHASE3	COMPLETED	A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain
NCT02683239	PHASE3	COMPLETED	Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
NCT03161093	PHASE3	COMPLETED	A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
NCT03285646	PHASE3	TERMINATED	Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
NCT03304379	PHASE3	COMPLETED	Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
NCT00944892	PHASE1/PHASE2	COMPLETED	A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee
NCT00991172	PHASE2	COMPLETED	A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain
NCT01001715	PHASE2	TERMINATED	Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain
NCT01001923	PHASE2	TERMINATED	Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain
NCT01239017	PHASE2	WITHDRAWN	A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee
NCT03691974	PHASE2	COMPLETED	Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee
NCT03949673	PHASE2	TERMINATED	Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip
NCT00856310	PHASE1	COMPLETED	A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects
NCT02516618	PHASE1	COMPLETED	Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).